Apogee Therapeutics (APGE) Short-term Investments (2023 - 2026)

Apogee Therapeutics (APGE) has 4 years of Short-term Investments data on file, last reported at $608.1 million in Q1 2026.

• On a quarterly basis, Short-term Investments rose 49.63% year-over-year to $608.1 million in Q1 2026; TTM through Mar 2026 was $608.1 million, a 49.63% increase from a year earlier, with the FY2025 full-year figure at $598.6 million, up 58.01% from the prior year.
• Short-term Investments for Q1 2026 stood at $608.1 million, up from $598.6 million in the prior quarter.
• Over the last five years, Short-term Investments for APGE reached as high as $608.1 million in Q1 2026 and fell as low as $234.6 million in Q3 2023.
• Historically, Short-term Investments has averaged $401.0 million across 4 years, with a median of $381.2 million in 2025.
• Across the five-year window, Short-term Investments surged 73.63% in 2024 and advanced 2.96% in 2025, its largest moves.
• Year by year, Short-term Investments stood at $277.1 million in 2023, then soared by 36.7% to $378.9 million in 2024, then jumped by 58.01% to $598.6 million in 2025, then increased by 1.58% to $608.1 million in 2026.
• Per Business Quant data, the three most recent Short-term Investments figures were $608.1 million in Q1 2026, $598.6 million in Q4 2025, and $419.4 million in Q3 2025.